MedTrace Logo

Anlotinib Therapy in Patients With Advanced Lung Cancer.

NCT03940404 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2019-05-07

No results posted yet for this study

Summary

Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world.

Subjects of the study: advanced Lung cancer.

Methods of the study:

This is a real world, prospective, Non-Interventional, Follow-up registration study.

Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle.

End point:

Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).

Conditions

  • Lung Neoplasms

Interventions

DRUG

Anlotinib Hydrochloride

Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.

Sponsors & Collaborators

  • Cttq

    collaborator INDUSTRY

  • First People's Hospital of Hangzhou

    lead OTHER

Principal Investigators

  • Shenglin Ma · First People's Hospital of Hangzhou

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2020-05-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940404 on ClinicalTrials.gov